CN Patent

CN104961681B — 卡博替尼的粘酸盐及其晶型

Assigned to Crystal Pharmatech Co Ltd · Expires 2017-06-13 · 9y expired

What this patent protects

本发明涉及N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑N’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的粘酸盐及其晶型和制备方法。本发明的式(Ⅰ)化合物的粘酸盐，其溶解度比之苹果酸盐更高，对于提高药物的生物利用度、药物疗效及安全性具有重要意义。。

USPTO Abstract

本发明涉及N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑N’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的粘酸盐及其晶型和制备方法。本发明的式(Ⅰ)化合物的粘酸盐，其溶解度比之苹果酸盐更高，对于提高药物的生物利用度、药物疗效及安全性具有重要意义。。

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN104961681B
Jurisdiction: CN
Classification: —
Expires: 2017-06-13
Drug substance claim: No
Drug product claim: No
Assignee: Crystal Pharmatech Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.